17.11.20: Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020

Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular diseaseIn the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes, overall finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease / People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that specifically addresses MR overactivation, a key driver of disease progressionmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news